The phrase "advance market commitments" is correct and usable in written English.
It can be used in discussions related to economics, finance, or public health, particularly when referring to agreements made in advance to purchase a product or service, often to encourage production or investment.
Example: "The government announced advance market commitments to ensure that vaccines are available for all citizens."
Alternatives: "pre-purchase agreements" or "forward market commitments".
But pilot projects suggest the new policy may work.Yet another incentive-based approach bubbling up is Advance Market Commitments (AMC).
The agreement is the first example of GAVI's program called advance market commitments, in which donor money is used to essentially guarantee a market for vaccine companies if they undertake development of vaccines for poor countries, or if the companies agree to build extra capacity to supply those markets with an existing vaccine.
To encourage further discovery, researchers and policymakers are promoting new economic models of vaccine development, including prizes, tax incentives, and advance market commitments.
Over the last decade, a number of initiatives have emerged to address these issues including Advance Market Commitments, product development partnerships, patent pools, and prizes to reward innovation.
Pneumococcal conjugate vaccines, including PHiD-CV, are being introduced in African countries under the Advance Market Commitments for pneumococcal disease piloted by GAVI [ 2].
This could be through tax incentives on research equipment and raw materials, as well as local "advance market commitments", whereby the Ministry of Health guarantees purchase of products developed locally as long as they meet internationally accepted standards.
The countries involved in the Advance Market Commitment project decided to start with the pneumococcal vaccine because it could be brought to market quickly.
Finance ministers of the UK, Italy, Canada, Russia and Norway, together with the Bill and Melinda Gates Foundation, agreed in 2009 to support what they called an advance market commitment (AMC).
Dr. von Schoen-Angerer said that the multibillion-dollar cost of the project was straining GAVI's finances and that the success of the pneumococcal program should be evaluated before the advance market commitment strategy was tried for another vaccine.
However, under an arrangement called the Advance Market Commitment that was brokered by GAVI to entice vaccine companies to keep supplying poor countries, both companies get an additional $3.50 for the first six million shots.
Creative financing from multilateral donors (in the form of "advance market commitment") and non-governmental outfits such as the GAVI Alliance is spurring interest in the neglected diseases of the poor world.
